Advancing Aortic Technologies
July 27, 2022
Artivion Initiates Enrollment in PERSEVERE Clinical Trial
Study Designed to Evaluate the Safety and Efficacy of the AMDS Hybrid Prosthesis to Treat Acute DeBakey Type I Aortic Dissections & Support U.S. FDA PMA Submission.
FDA Accepts CryoLife IDE Application for PERSEVERE Pivotal IDE Study
A Prospective, Single Arm, Multi-center Clinical Investigation, to Evaluate the Saftey and Effectiveness of AMDSTM in the Treatment of Acute DeBakey Type I Dissection
July 29, 2021
CryoLife Announces Sale of PerClot to Baxter
CryoLife Announces the Sale of PerClot to a subsidiary of Baxter International, Inc.
September 2, 2020
CryoLife Acquires Ascyrus Medical
CryoLife Acquires Ascyrus Medical LLC, Developer of AMDS Hybrid Prosthesis. Ascyrus is a Florida-based, privately-held developer of the Ascyrus Medical Dissection Stent (AMDS™), the world’s first aortic arch remodeling device used for the treatment of acute Type A aortic dissections.
When the need is aortic,
the solution is Artivion
Our intentional focus on the aorta and collaboration with the world’s foremost cardiac and vascular surgeons allow us to leverage our combined expertise in the development of new, innovative, life-changing aortic-centric technologies.
Please contact your local Artivion representative for details.
CARDIAC & VASCULAR
- CRYOVALVE® SG PULMONARY HUMAN HEART VALVE
- CRYOVALVE® AORTIC ALLOGRAFT
- CRYOPATCH® SG PULMONARY PATCH
- CRYOGRAFT® DESCENDING THORACIC AORTA
- CRYOARTERY® AORTOILIAC ARTERY
- CRYOARTERY® FEMORAL ARTERY
- CRYOVEIN® SAPHENOUS VEIN
- CRYOVEIN® FEMORAL VEIN
- CRYOVEIN® PC PEDIATRIC CONDUIT
- CRYOPATCH® AUTOLOGOUS PERICARDIUM
CARDIAC & VASCULAR
E-XTRA DESIGN ENGINEERING
We provide solutions that have far-reaching impact on surgical outcomes and restoring the lives of patients fighting aortic diseases. Cardiac and vascular surgeons the world over—along with each patient in their care—have greatly benefited from our life-changing technologies.